Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

2.

Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.

Kleinschmidt EG, Miller NLG, Ozmadenci D, Tancioni I, Osterman CD, Barrie AM, Taylor KN, Ye A, Jiang S, Connolly DC, Stupack DG, Schlaepfer DD.

Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.

PMID:
31308489
3.

Nuclear Focal Adhesion Kinase Controls Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia Through GATA4-Mediated Cyclin D1 Transcription.

Jeong K, Kim JH, Murphy JM, Park H, Kim SJ, Rodriguez YAR, Kong H, Choi C, Guan JL, Taylor JM, Lincoln TM, Gerthoffer WT, Kim JS, Ahn EE, Schlaepfer DD, Lim SS.

Circ Res. 2019 Jul 5;125(2):152-166. doi: 10.1161/CIRCRESAHA.118.314344. Epub 2019 May 17.

PMID:
31096851
4.

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS.

Cancer Cell. 2019 Mar 18;35(3):457-472.e5. doi: 10.1016/j.ccell.2019.01.009. Epub 2019 Feb 14.

PMID:
30773340
5.

Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage.

Taylor KN, Schlaepfer DD.

Mol Cancer Ther. 2018 Apr;17(4):719-723. doi: 10.1158/1535-7163.MCT-17-1177.

6.

Focal adhesion kinase signaling in unexpected places.

Kleinschmidt EG, Schlaepfer DD.

Curr Opin Cell Biol. 2017 Apr;45:24-30. doi: 10.1016/j.ceb.2017.01.003. Epub 2017 Feb 16. Review.

7.

Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.

Delaney JR, Patel CB, Willis KM, Haghighiabyaneh M, Axelrod J, Tancioni I, Lu D, Bapat J, Young S, Cadassou O, Bartakova A, Sheth P, Haft C, Hui S, Saenz C, Schlaepfer DD, Harismendy O, Stupack DG.

Nat Commun. 2017 Feb 15;8:14423. doi: 10.1038/ncomms14423.

8.

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM.

Nat Med. 2016 May;22(5):497-505. doi: 10.1038/nm.4082. Epub 2016 Apr 18.

9.

Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 expression.

Yurdagul A Jr, Sulzmaier FJ, Chen XL, Pattillo CB, Schlaepfer DD, Orr AW.

J Cell Sci. 2016 Apr 15;129(8):1580-91. doi: 10.1242/jcs.182097. Epub 2016 Feb 18.

10.

A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.

Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG.

Oncotarget. 2015 Oct 13;6(31):31104-18. doi: 10.18632/oncotarget.5093.

11.

FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.

Gao C, Chen G, Kuan SF, Zhang DH, Schlaepfer DD, Hu J.

Elife. 2015 Sep 3;4. doi: 10.7554/eLife.10072.

12.

Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.

Young SA, McCabe KE, Bartakova A, Delaney J, Pizzo DP, Newbury RO, Varner JA, Schlaepfer DD, Stupack DG.

PLoS One. 2015 May 14;10(5):e0120815. doi: 10.1371/journal.pone.0120815. eCollection 2015.

13.

Gastrin-stimulated Gα13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.

Masià-Balagué M, Izquierdo I, Garrido G, Cordomí A, Pérez-Benito L, Miller NL, Schlaepfer DD, Gigoux V, Aragay AM.

J Biol Chem. 2015 Jun 12;290(24):15197-209. doi: 10.1074/jbc.M114.628164. Epub 2015 Apr 28.

14.

FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.

Tancioni I, Miller NL, Uryu S, Lawson C, Jean C, Chen XL, Kleinschmidt EG, Schlaepfer DD.

Breast Cancer Res. 2015 Mar 28;17:47. doi: 10.1186/s13058-015-0551-x.

15.

FAK in cancer: mechanistic findings and clinical applications.

Sulzmaier FJ, Jean C, Schlaepfer DD.

Nat Rev Cancer. 2014 Sep;14(9):598-610. doi: 10.1038/nrc3792. Epub 2014 Aug 7. Review.

16.

FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD.

Mol Cancer Ther. 2014 Aug;13(8):2050-61. doi: 10.1158/1535-7163.MCT-13-1063. Epub 2014 Jun 4.

17.

Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD.

Gynecol Oncol. 2014 Jul;134(1):104-11. doi: 10.1016/j.ygyno.2014.04.044. Epub 2014 Apr 27.

18.

RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.

Miller NL, Kleinschmidt EG, Schlaepfer DD.

Curr Mol Med. 2014 Feb;14(2):221-34. Review.

19.

Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.

Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh DA, Schlaepfer DD.

J Cell Biol. 2014 Jan 20;204(2):247-63. doi: 10.1083/jcb.201307067.

20.

Grb2 promotes integrin-induced focal adhesion kinase (FAK) autophosphorylation and directs the phosphorylation of protein tyrosine phosphatase α by the Src-FAK kinase complex.

Cheng SY, Sun G, Schlaepfer DD, Pallen CJ.

Mol Cell Biol. 2014 Feb;34(3):348-61. doi: 10.1128/MCB.00825-13. Epub 2013 Nov 18.

21.

pHocal adhesion kinase regulation is on a FERM foundation.

Lawson C, Schlaepfer DD.

J Cell Biol. 2013 Sep 16;202(6):833-6. doi: 10.1083/jcb.201308034.

22.

A non-canonical role for Rgnef in promoting integrin-stimulated focal adhesion kinase activation.

Miller NL, Lawson C, Kleinschmidt EG, Tancioni I, Uryu S, Schlaepfer DD.

J Cell Sci. 2013 Nov 1;126(Pt 21):5074-85. doi: 10.1242/jcs.135509. Epub 2013 Sep 4.

23.

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe SC, Schlaepfer DD.

Clin Exp Metastasis. 2013 Jun;30(5):579-94. doi: 10.1007/s10585-012-9562-5. Epub 2012 Dec 30.

24.

Tetraspan TM4SF5-dependent direct activation of FAK and metastatic potential of hepatocarcinoma cells.

Jung O, Choi S, Jang SB, Lee SA, Lim ST, Choi YJ, Kim HJ, Kim DH, Kwak TK, Kim H, Kang M, Lee MS, Park SY, Ryu J, Jeong D, Cheong HK, Kim HJ, Park KH, Lee BJ, Schlaepfer DD, Lee JW.

J Cell Sci. 2012 Dec 15;125(Pt 24):5960-73. doi: 10.1242/jcs.100586. Epub 2012 Oct 17.

25.

Integrin adhesions: who's on first? What's on second? Connections between FAK and talin.

Lawson C, Schlaepfer DD.

Cell Adh Migr. 2012 Jul-Aug;6(4):302-6. doi: 10.4161/cam.20488. Epub 2012 Jul 1.

26.

Cortactin as a target for FAK in the regulation of focal adhesion dynamics.

Tomar A, Lawson C, Ghassemian M, Schlaepfer DD.

PLoS One. 2012;7(8):e44041. doi: 10.1371/journal.pone.0044041. Epub 2012 Aug 29.

27.

Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.

Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh DA, Schlaepfer DD.

J Cell Biol. 2012 Jun 25;197(7):907-19. doi: 10.1083/jcb.201109067.

28.

Rgnef (p190RhoGEF) knockout inhibits RhoA activity, focal adhesion establishment, and cell motility downstream of integrins.

Miller NL, Lawson C, Chen XL, Lim ST, Schlaepfer DD.

PLoS One. 2012;7(5):e37830. doi: 10.1371/journal.pone.0037830. Epub 2012 May 23.

29.

EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.

Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA.

PLoS One. 2012;7(5):e36753. doi: 10.1371/journal.pone.0036753. Epub 2012 May 7.

30.

FAK promotes recruitment of talin to nascent adhesions to control cell motility.

Lawson C, Lim ST, Uryu S, Chen XL, Calderwood DA, Schlaepfer DD.

J Cell Biol. 2012 Jan 23;196(2):223-32. doi: 10.1083/jcb.201108078. Erratum in: J Cell Biol. 2012 Feb 6;196(3):387.

31.

VEGF-induced vascular permeability is mediated by FAK.

Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD.

Dev Cell. 2012 Jan 17;22(1):146-57. doi: 10.1016/j.devcel.2011.11.002.

32.

Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells.

Li XY, Zhou X, Rowe RG, Hu Y, Schlaepfer DD, Ilić D, Dressler G, Park A, Guan JL, Weiss SJ.

J Cell Biol. 2011 Nov 28;195(5):729-38. doi: 10.1083/jcb.201105103. Epub 2011 Nov 21.

33.

EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.

Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA.

Oncogene. 2012 May 31;31(22):2783-93. doi: 10.1038/onc.2011.450. Epub 2011 Oct 3.

34.

Detection of focal adhesion kinase activation at membrane microdomains by fluorescence resonance energy transfer.

Seong J, Ouyang M, Kim T, Sun J, Wen PC, Lu S, Zhuo Y, Llewellyn NM, Schlaepfer DD, Guan JL, Chien S, Wang Y.

Nat Commun. 2011 Jul 26;2:406. doi: 10.1038/ncomms1414.

35.

p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.

Yu HG, Nam JO, Miller NL, Tanjoni I, Walsh C, Shi L, Kim L, Chen XL, Tomar A, Lim ST, Schlaepfer DD.

Cancer Res. 2011 Jan 15;71(2):360-70. doi: 10.1158/0008-5472.CAN-10-2894. Epub 2011 Jan 11.

36.

Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation.

Lim ST, Chen XL, Tomar A, Miller NL, Yoo J, Schlaepfer DD.

J Biol Chem. 2010 Jul 9;285(28):21526-36. doi: 10.1074/jbc.M110.129999. Epub 2010 May 4.

37.

Myosin II activity regulates vinculin recruitment to focal adhesions through FAK-mediated paxillin phosphorylation.

Pasapera AM, Schneider IC, Rericha E, Schlaepfer DD, Waterman CM.

J Cell Biol. 2010 Mar 22;188(6):877-90. doi: 10.1083/jcb.200906012.

38.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):778-90.

39.

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.

Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.

Cancer Biol Ther. 2010 May 15;9(10):764-77.

40.

A PAK-activated linker for EGFR and FAK.

Tomar A, Schlaepfer DD.

Dev Cell. 2010 Feb 16;18(2):170-2. doi: 10.1016/j.devcel.2010.01.013.

41.

Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.

Lim ST, Miller NL, Nam JO, Chen XL, Lim Y, Schlaepfer DD.

J Biol Chem. 2010 Jan 15;285(3):1743-53. doi: 10.1074/jbc.M109.064212. Epub 2009 Oct 30.

42.

Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility.

Tomar A, Schlaepfer DD.

Curr Opin Cell Biol. 2009 Oct;21(5):676-83. doi: 10.1016/j.ceb.2009.05.006. Epub 2009 Jun 12. Review.

43.

A FAK-p120RasGAP-p190RhoGAP complex regulates polarity in migrating cells.

Tomar A, Lim ST, Lim Y, Schlaepfer DD.

J Cell Sci. 2009 Jun 1;122(Pt 11):1852-62. doi: 10.1242/jcs.046870. Epub 2009 May 12. Erratum in: J Cell Sci. 2009 Aug 15;122(Pt 16):3005.

44.

Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility.

Vomaske J, Melnychuk RM, Smith PP, Powell J, Hall L, DeFilippis V, Früh K, Smit M, Schlaepfer DD, Nelson JA, Streblow DN.

PLoS Pathog. 2009 Feb;5(2):e1000304. doi: 10.1371/journal.ppat.1000304. Epub 2009 Feb 20.

45.

Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.

Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh DA.

Cancer Res. 2009 Feb 15;69(4):1383-91. doi: 10.1158/0008-5472.CAN-08-3612. Epub 2009 Feb 10.

46.

Establishment of cell lines from mouse embryos with early embryonic lethality.

Howerton K, Schlaepfer DD, Ilic D.

Cell Commun Adhes. 2008 Nov;15(4):379-83. doi: 10.1080/15419060802440054.

47.

FERM control of FAK function: implications for cancer therapy.

Lim ST, Mikolon D, Stupack DG, Schlaepfer DD.

Cell Cycle. 2008 Aug;7(15):2306-14. Epub 2008 May 29. Review.

48.

FAK nuclear export signal sequences.

Ossovskaya V, Lim ST, Ota N, Schlaepfer DD, Ilic D.

FEBS Lett. 2008 Jul 9;582(16):2402-6. doi: 10.1016/j.febslet.2008.06.004. Epub 2008 Jun 10.

49.

Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK.

Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, Shen TL, Guan JL, Schlaepfer DD, Cheresh DA.

J Cell Biol. 2008 Apr 7;181(1):43-50. doi: 10.1083/jcb.200710038.

50.

Analyzing FAK and Pyk2 in early integrin signaling events.

Bernard-Trifilo JA, Lim ST, Hou S, Schlaepfer DD, Ilic D.

Curr Protoc Cell Biol. 2006 Apr;Chapter 14:Unit 14.7. doi: 10.1002/0471143030.cb1407s30.

PMID:
18228476

Supplemental Content

Loading ...
Support Center